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Multiple Endocrine Neoplasia Type 1
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Multiple endocrine neoplasia-1 (MEN-1) is an autosomal dominant inherited
syndrome that occurs due to inactivating mutations of the MEN1 gene locus, coding
for a tumor-suppressor protein, menin. The components of MEN-1 are hyperpar-
athyroidism due to multiple parathyroid adenomas, pancreatic neuroendocrine tumors,
and pituitary adenomas, in addition to some less common neoplastic manifestations.
Care of people with MEN-1 requires knowledge of the problems that may arise, and
the best approaches to detect and care for the manifestations of this incurable, but
manageable, disease.
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Multiple endocrine neoplasia type 1 is an autosomal
dominant inherited syndrome that occurs due to inacti-
vating mutations of the MEN1 gene locus, coding for a
tumor-suppressor protein, menin. Inactivation of one copy
of the menin protein-coding alleles, allows neoplasia to
occur after an inactivating somatic mutation of the
remaining allele (consistent with the Knudsen two-hit
hypothesis). The clinical syndrome of MEN-1 classically
includes hyperparathyroidism due to multiple parathy-
roid adenomas, pancreatic neuroendocrine tumors, and
pituitary adenomas. In addition, MEN-1 carriers can have
multiple lipomas, adrenal or thyroid adenomas, cuta-
neous angiofibromas, and bronchial or thymic carcinoid
tumors.
CLINICAL PRESENTATION
The peak incidence of symptoms in women with
MEN-1 is during the third decade of life, whereas the
peak incidence in men is during the fourth decade [1].
MEN-1 can usually be detected in individuals from
known MEN-1 kindreds by the age of 25 by clinical
screening; if the gene defect in the affected family has
been defined, direct genetic testing can be used at any age
[2]. Specimens for sequencing of the MEN1 gene should
only be processed if the clinical diagnosis in the proband
is clear. Testing is not indicated for patients with an
equivocal clinical diagnosis of MEN-1. More than one-
half of patients with MEN-1 have clinical involvement of
more than one organ system, and approximately 20%
have three affected endocrine glands. The frequency
of clinical signs and symptoms, in descending order, is
hypercalcemia, nephrolithiasis, peptic ulcer disease, hypo-
glycemia, headache, visual field loss, hypopituitarism,
acromegaly, galactorrhea-amenorrhea, and rarely Cush-
ing’s syndrome. Patients with MEN-1 have a decreased
life expectancy, with a 50% probability of death by age
50. One-half of the deaths are due to a malignant tumoral
process or a sequela of the disease [3–5]. Separation of
the patient’s potential or actual problems into the various
affected organs aids in the deliberate management of
these complex patients.
PARATHYROID DISEASE
Asymmetric multigland primary hyperparathyroidism
is the most frequent feature of MEN-1. Studies have
demonstrated that there is a monoclonal abnormality in
the enlarged parathyroid glands of patients with MEN-1,
suggesting that the process in these glands may not be
dependent on a circulating factor (hyperplasia) but rather
occurs through inactivation of the MEN-1 gene in a pre-
cursor cell (neoplasia) [6]. The relationship of asymmetry
of affected glands to patient age (younger patients more
frequent asymmetric involvement, older patients with
involvement of all glands) and the tumor suppressor
genetic basis of the syndrome, favor the occurrence of
multiple adenomas (neoplasia) rather than hyperplasia [7].
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Primary hyperparathyroidism occurs in 88%–97% of
MEN-1-affected patients. The diagnosis is dependent on
the detection of elevated serum levels of calcium and
parathyroid hormone. Primary hyperparathyroidism is
usually the initially recognized clinical manifestation of
patients with MEN-1, although in prospectively screened
patients, other manifestations may be detected earlier
biochemically [2,8]. The most frequent symptomatic
tumor in teenagers with MEN-1 is insulinoma; occasional
patients have clinical manifestations of Zollinger–
Ellison syndrome (ZES) before primary hyperparathyr-
oidism. The pathology associated with primary hyperpar-
athyroidism is always multiple gland disease. Although
some glands may appear grossly normal, the likelihood of
finding normal-weight glands decreases as the age of the
patient increases, consistent with the development of
multiple parathyroid adenomas [7].
The surgical management requires a strategy that
acknowledges that all of the parathyroid glands are, or
will be, abnormal, and that the patient is better served by
having a smaller amount of abnormal parathyroid tissue,
than by having none at all. Options include removal of
three and a half glands leaving a part of one gland in the
neck, or removing all four parathyroid glands with
immediate autograft of some of the parathyroid tissue
into the musculature of the non-dominant forearm.
Neither strategy yields ideal results. The incidence of
recurrent or persistent hyperparathyroidism is 16%–
54%, and the incidence of hypoparathyroidism is be-
tween 10% and 25% [9,10]. Re-operations are frequently
necessary, and similar principles should be applied.
PANCREATIC ENDOCRINE DISEASE
Malignant pancreatic endocrine tumors are the most
common MEN-1–related cause of death in MEN-1
kindreds [3–5]. Pathologic examination of the duodenum
and pancreas in patients with MEN-1 demonstrates
multiple neuroendocrine tumors [11,12]. Tumors produc-
ing pancreatic polypeptide are the most common pan-
creatic endocrine tumor in MEN-1 patients, occurring in
80%–100%. These tumors cause symptoms only due to
the tumor mass itself and thus often present when tumor
growth is advanced. Many patients develop functional
pancreatic endocrine tumors, sometimes coincident
with pancreatic polypeptide-producing tumors, of whom
most have gastrinoma, approximately 20% insulinoma,
3% glucagonoma, and 1% vasoactive intestinal peptide
(VIPoma).
The natural history of pancreatic disease in MEN-1 has
been difficult to define in the past because of the rarity of
the disease and significant variability in the virulence of
the pancreatic malignancy. However, three recent studies
have identified significant mortality associated with the
pancreatic islet cell tumors, a natural history that
demands intervention in that group of patients with
virulent malignancy. The studies evaluated patients from
Tasmania, and those followed at Washington University
and the Mayo Clinic [3–5].
In the Washington University study, the database
contained 34 distinct kindreds with 1,838 members.
Reliable death data were available for 103 people and
survival curves of MEN-1 patients who died from causes
related to MEN-1, were compared to MEN-1 carriers
who died from a non-endocrine cause, and to unaffected
kindred member [3]. The ages of death were contrasted
between affected and unaffected members of MEN-1
kindreds. Of 59 MEN-1 affected patients, 27 died directly
of MEN-1-specific illness, and 32 died of non-MEN-1
causes. The MEN-1-specific deaths occurred younger
(median 47 years) than either MEN-1 patients whose
death was from some non-endocrine cause (median
60 years, P< 0.02), or than all kindred members who did
not die of MEN-1 disease (median 55 years, P< 0.05).
The causes of death in the MEN-1 patients included islet
cell tumor (12 patients), ulcer disease (6 patients),
hypercalcemia/uremia (3 patients), carcinoid tumor
(6 patients), and non-endocrine malignancies (9 patients).
MEN-1 carriers did not have a difference in survival
compared to unaffected kindred members. Thus, of the
Washington University MEN-1 patients, 46% died from
causes related to their endocrine tumors after a median
of 47 years, which was younger than family members
who did not die of these tumors, and the most frequent
cause of death, especially in the more recent years of the
study, was pancreatic islet cell tumors. In addition,
the metastatic islet cell tumors accounted for some of
the youngest deaths in the study median age 46 (range
27–89).
The Tasman and Mayo Clinic series are similar. In
the Tasman series, there were 46 deaths in patients with
MEN-1, 20 of which were caused by components of the
disease (44%) [4]. Of these, only three were due to
metastatic islet cell tumor; however, each of these three
were in the most recent decade of the study, when the
patients were best evaluated and characterized. TheMayo
Clinic series included 60 deaths, of which only 17 were
clearly related to MEN-1 (28%), however, 10 of these
were due to metastatic islet cell tumor [5]. The combined
series includes 64 deaths clearly related to MEN-1, 43 of
which were due directly to malignant neoplasms, and
25 of which were malignant islet cell tumors. Thus, the
natural history of MEN-1 justifies an aggressive screen-
ing program with early therapeutic intervention when a
tumor is identified.
To date, no studies have demonstrated that surgical
resection of pancreatic neuroendocrine tumors in MEN-1
is beneficial. One study suggests that surgical resection
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of primary gastrinomas in patients with and without
MEN-1 decreases the probability of the development of
liver metastases, which is the most important negative
predictor of survival [13]. Based on these data, patients
with positive imaging studies and no evidence of un-
resectable metastases should undergo surgical explora-
tion with intraoperative ultrasound. Tumors larger than
1 cm identified in the pancreatic head are enucleated, the
duodenum is carefully explored by duodenotomy, and
solitary or multiple tumors identified are resected; large
tumors in the pancreatic body or tail are removed by
distal pancreatectomy and splenectomy [14]. Resection
of liver metastases from patients with MEN-1 may also
be beneficial. Using this approach, while cure of ZES is
unusual, resection should reduce the risk of subsequent
metastatic disease. No data conclusively demonstrate that
this approach increases survival, although case series are
suggestive [15].
The surgical management of insulinoma and VIPoma
in MEN-1 patients has more frequent biochemical cures
than resection for gastrinoma. Medical management of
the watery diarrhea in VIPoma is effective using either
short-acting or depot somatostatin analogues. Hypogly-
cemia management in insulinoma is not reliable.
Diazoxide and octreotide are available and may be useful
for short-term treatment. In patients with MEN-1, insuli-
noma and VIPoma are frequently solitary large tumors.
Resection may result in cure [15].
The most controversial issue in MEN-1 management is
probably the decision to intervene in the pancreatic
disease. Based on the data that implicate the pancreatic
tumors as a potentially lethal lesion, and resection as the
only option to prevent or delay this, all macroscopic
tumors of the MEN-1 pancreas should be regarded as
potentially malignant, and neither tumor size nor radio-
logical findings or peptide production can safely be used
as markers of malignancy [16]. Time may be an important
risk factor for mutagenetic events essential for malignant
transformation [17]. In addition, 50% of middle-aged
patients display metastases. The prevention of death from
metastatic islet cell tumor requires pancreatic surgery
before frank clinical syndromes occur, in relatively young
MEN-1 patients, based on active surveillance programs.
Surveillance for pancreatic endocrine tumors in patients
with the MEN-1 mutation is a critical part of the
management of adult patients. The options for surveil-
lance include (1) hormone measurements, (2) cross-
sectional imaging, (3) somatostatin-receptor scintigraphy,
and (4) endoscopic ultrasonography. Although pancreatic
endocrine tumors can occur in people with an MEN-1
mutation during childhood, they are almost always
insulinomas that declare themselves by symptoms.
Surveillance for these tumors is not necessary until
adulthood.
Biochemical Surveillance
Hormone measurements have been useful to screen
for pancreatic tumors in MEN-1 because of the frequent
functional nature of the tumors [2,18,19]. Efficient
programs have been designed for clinical recognition of
the lesions. Patients can be screened biochemically, either
with or without a provocative agent, such as a standard
meal, calcium or secretin. The results of the biochemical
testing can then be used to select patients for imaging.
Biochemical testing is useful for annual or semiannual
evaluation of asymptomatic gene carriers. Patients with
specific symptoms require investigation by other means.
The advantage of biochemical testing is that patients
can be identified as harboring functional pancreatic
endocrine tumors in a pre-symptomatic state. The dis-
advantages of the biochemical testing are that some
tumors make insufficient hormone to be identified, and
some patients harbor tumors that are identifiable bio-
chemically, but not imageable at that point [2]. This can
lead to extensive testing and possibly operation that is
unlikely to benefit the patient clinically.
A standard annual biochemical screening program has
been advocated by Dr. Skogseid and her colleagues from
the University of Uppsala. In their program, within their
annual visit that also includes evaluation for parathyroid
and pituitary disease, patients have baseline levels of
insulin, proinsulin, glucagon, pancreatic polypeptide, and
gastrin, followed by meal-stimulated levels of gastrin and
pancreatic polypeptide. This approach identified pan-
creatic tumors as the initial presenting abnormality in
several patients, and identified tumors at an early stage.
However, the biochemical screening, and particularly the
meal test, can generate some false-positive results. Mild
elevations in the biochemical screening must be repeated
after an interval to establish confidence that it reflects
pancreatic endocrine neoplasia [20].
Efforts to replace the standard meal test with a pro-
vocative test using calcium and secretin have been stalled
by the unavailability of secretin, and the uncomfortable
nature of the calcium infusion [21]. However, the infusion
of calcium (2 mg/kg) and secretin (2 U/kg) in ten known
MEN-1 carriers did demonstrate marked differences in
induced (2-min peak) serum levels of pancreatic poly-
peptide, gastrin, and insulin compared to normal volun-
teers. The elevation of hormone levels was also correlated
with the presence of imageable tumors.
Cross-Sectional Imaging and Somatostatin-Receptor
Scintigraphy Surveillance
Evaluation with cross-sectional imaging, such as
computed tomography scan, can demonstrate tumors in
the pancreas, regional lymph nodes, and hepatic metas-
tases (Figs. 1 and 2). This modality has the advantage of
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identifying tumors anatomically, which can provide
information useful for clinical decisions about resection.
In addition, by definition, CT scan will not identify
tumors that cannot then be found. The disadvantage of CT
scan is that it identifies lesions, without regard to their
histology or function. Thus, lesions identified in the
pancreas, or more commonly, in adjacent nodes, may be
irrelevant findings independent of the MEN-1 syndrome.
Prospective studies that have evaluated the sensitivity of
CT imaging to detect pancreatic endocrine tumors, have
found that it is significantly less sensitive than biochem-
ical testing in identifying early disease [2]. Thus, for
surveillance, CT is less useful, but for establishing the
anatomic extent of disease after biochemical diagnosis,
CT is critical.
Somatostatin-receptor scintigraphy can identify
lesions in and around the pancreas and liver, as well as
throughout the remainder of the body (Fig. 3). SRS has
the advantage of identifying tumors functionally, based
on the size of the tumor mass and the concentration of
somatostatin receptors [22,23]. The disadvantage of
SRS lies in its lack of anatomic specificity. The nuclear
medicine images, even with SPECT cross-sectional
imaging, provide only general anatomic definition with
respect to surrounding organs. SRS must always, there-
fore, be combined with CT scan or other anatomic
imaging techniques to provide anatomic correlates to the
scintigraphic findings. In addition, SRS has the advantage
of identifying other potential sites of disease, including
intrathoracic disease from either metastases of the
pancreatic primary, or carcinoid tumors of the thymus
or bronchus.
In a prospective study of SRS in MEN-1 patients, 37
SRS studies were performed in 29 MEN-1 patients [22].
SRS identified occult tumor in 36% (4/11) of patients
with only biochemical evidence of neuroendocrine
tumor; two patients went on to resection. SRS showed
tumor in 79% (15/19) of patients with CT-demonstrated
tumor; 30% (6/20) of the SRS lesions were occult on CT.
Conversely, 55% (16/29) of CT-identified lesions were
occult on SRS. SRS found distant disease in 21% (6/29)
of patients. In previously operated patients, SRS found
tumor in 40% (4/10) of patients, again with both new
positives and false negatives compared to other imaging.
SRS also had three important false-positive results,
including one patient who had laparotomy with no tumor
identified. Thus, SRS was useful in identifying otherwise
occult neuroendocrine tumors in MEN-1 patients and
substantially altered management. However, SRS also
has significant false-positive and false-negative results
which demand correlation with other studies.
Fig. 1. CT scan from a patient with multiple pancreatic neuro-
endocrine tumors. The tumors can demonstrate a variety of CT
characteristics, as in this example. The tumors can be hypervascular,
hypovascular, or similar to the surrounding pancreas and only
distinguished by the nodular appearance.
Fig. 2. The typical appearance of a metastatic lesion to the liver from
a pancreatic neuroendocrine tumor (same patient as in Fig. 1). This
lesion, and two other metastases, and the patient multiple pancreatic




Endoscopic ultrasound is the most sensitive imaging
modality for small pancreatic endocrine tumors. Its
advantage lies in the ability to image the parenchyma
of the pancreas and the immediately peri-pancreatic
lymph nodes with exquisite precision. The disadvantage
of the EUS is that it cannot image any of the other
potential sites of disease, such as the liver or chest. In a
retrospective review of EUS in MEN-1 patients screened
at the University of Michigan, 14 of 15 asymptomatic
patients were found to have pancreatic tumors (12 with
multiple lesions) with a median size of 1.5 cm (range
0.6–6.5 cm) [24]. Many of these lesions were at or below
the level of reliable detection of other imaging moda-
lities, such as CT scan, and the EUS also provided detail-
ed anatomic information useful for operative planning.
The EUS was not useful for identifying duodenal wall
gastrinomas, which are frequent in MEN-1. Because of
its tremendous sensitivity in the pancreas, but limited
anatomic scope, the EUS may be useful for a specific role
in MEN-1 screening, to identify otherwise occult tumors
in the asymptomatic patient.
A unified surveillance plan for pancreatic endocrine
tumors in MEN-1 should take advantage of the strengths
of each of these modalities. Biochemical assessment of
hormones can lead to detailed investigation, but should
probably not be the sole method. As the most sensitive
test, biochemical evaluation can reassure clinicians and
patients, and allow for other examinations at greater
intervals if the biochemistry remains normal from year to
year. For imaging examinations, a combination of CT
scan and SRS provides the best coverage of the abdomen
and thorax, to identify anatomic correlates to the func-
tional lesions revealed by biochemical testing, and should
be done at some interval even in the presence of normal
biochemistry, to evaluate for non-functional lesions.
Finally, the EUS appears to be useful in providing a very
sensitive assessment of the pancreas, and may be espe-
cially useful in patients with biochemical evidence of
tumor, but no imageable disease on SRS or CT scan. This
may also be of particular value in patients who have had a
previous partial pancreatectomy, which can complicate
the interpretation of the CT scan.
Management of the Functional Hormonal Syndrome
The hormonal syndromes associated with functional
PETs in MEN-1 should be managed as best as possible
prior to operation. The management of ZES is very nearly
perfect with proper medical regimens. Acid-suppression
therapy resolves the peptic ulcer disease and diarrhea.
Insulinoma syndrome is not well-palliated medically,
and requires operative resection in order to relieve the
syndrome. Management of VIPoma and glucagonoma
syndromes are greatly facilitated by the use of a soma-
tostatin analogue (octreotide) which can be administered
monthly as a long-acting formulation.
Operative Management of MEN-1 Pancreatic Disease
The operative management must be individualized
for each patient based on their pattern of disease. The
principles are complete tumor resection and preservation
of pancreatic function, by preserving as much grossly
normal pancreas as possible, while minimizing the
morbidity of the procedure [25–27]. In practice, this
often results in the subtotal resection of the distal
pancreas, and enucleation of tumors in the head of the
pancreas and duodenum. This operation removes the
gross disease in the distal pancreas, while preserving
most of the pancreatic mass in the head, and avoiding the
need for a pancreatic anastamosis. For patients with
Fig. 3. Somatostatin-receptor scintigraphy for the detection of pancreatic neuroendocrine tumor. The image is very helpful, but only if carefully
correlated with cross-sectional imaging to further localize the lesions.
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bulky disease in the head of the pancreas, however, which
may not be amenable to enucleation, a better option may
be pancreaticoduodenectomy, and enucleation of any
tumors in the tail. In all patients with gastrinoma, the
duodenum should be opened and submucosal tumors
resected. Occasional patients may have disease that can be
completely removed without formal pancreatic resection.
Total pancreatectomy is rarely indicated, or necessary, to
meet the goal of complete tumor resection.
A contemporary series of pancreatectomy in MEN-1
patients catalogues the operations and their outcomes at
Washington University between 1993 and 1999 [26].
Twenty-one consecutive patients with tumors identified
through an integrated disease screening program under-
went exploration, with the twin goals of complete tumor
resection and preservation of grossly normal pancreas. In
this series of patients, 5 required pancreaticoduodenect-
omy, 11 had non-whipple pancreatic resections, and 5
underwent enucleation of limited neuroendocrine tumors.
The morbidity of these operations was significant, and
two patients died in the perioperative period. One patient
developed fatal viral encephalitis 6 weeks after an
otherwise uneventful recovery. The other mortality was
in an elderly man with prohibitive pulmonary function
(FEV1< 700 ml) and uncontrollable hypoglycemia from
an insulinoma, who died of pulmonary failure following
resection. The morbidity of operation included a 14% rate
of anastomotic leak and abscess and a 10% rate of wound
infection. In these patients, the operative strategy was
able to render them disease-free in the short term, but
follow-up is currently insufficient to demonstrate efficacy
in this series.
In a similar study with more extended follow-up, the
University of Uppsala group detailed their approach in 20
patients, 12 of whom were symptomatic and 8 patients
identified by screening [17]. They followed the same
guidelines of complete tumor resection with preservation
of functional pancreatic mass. To date, none of the
patients whose tumors were identified by screening in
their study have developed metastatic disease. While
further follow-up of both this cohort and the Washington
University series is necessary to determine whether this
strategy will have a long-term benefit in reducing the
occurrence of death from malignant islet cell tumors, this
currently appears to be the most viable strategy.
One study has sufficient follow-up to allow some
conclusions regarding the effects of operation on out-
come [28]. Between 1967 and 2003, 39 patients, ages
19–58 (mean age 37.1), had abdominal operations for
their PETs: 26 with ZES, 4 with hypoglycemia, 3 with
both ZES and hypoglycemia, and 6 with non-functional
tumors. Fifteen of these 39 patients had malignant disease
on initial abdominal operation. Twenty-four of 39 patients
have not required abdominal re-operation, 17 of whom
have available follow-up data. Of these 17 patients,
11 have biochemical evidence of disease recurrence
(elevated gastrin, insulin or pancreatic polypeptide),
while 6 have no biochemical evidence of recurrence.
A total of 30 abdominal re-operations were performed
in 15 patients. Fourteen of 15 patients undergoing one
or more re-operations developed evident malignant
disease by their most recent operation. Nine of 13 re-
operative patients with follow-up data have evidence of
disease recurrence. Functional outcomes available in 20
patients showed that 10 patients require insulin injections
and 6 require oral hypoglycemics. Ninety percent have no
abdominal pain or nausea/vomiting, while four are unable
to return to work secondary to this disease. Seven patients
have died since initial operation, two from sequalae of
their pancreaticoduodenal NETs. These data demonstrate
that treatment of MEN-1 PETs is met with frequent
recurrence (Table I), even after re-operation to resect
additional or recurrent disease (Table II), and some
treatment-related morbidity and mortality. Most patients
(22 of 39) eventually demonstrated malignant growth, but
with this strategy, few died of this disease. The overall
survival of our series of MEN-1 patients undergoing
abdominal operation for pancreaticoduodenal NETs
shows that the median survival age for patients managed
with this strategy has not been reached. Thus, this appears
to be a viable approach to changing the natural history
defined in other studies.
PITUITARY DISEASE
Pituitary tumors occur in 54%–80% of patients with
MEN-1. Symptoms may be due to local encroachment










No recurrence 8 20.5 4.8 0.8–12.3
Recurrence and reoperation 15 38.5 9.9 3.1–30.0
Recurrence and no reoperation 12 30.8 6.3 0.1–11.0
Lost to follow-up 4 10.3 0.0
*From: Hausmann M et al. [28].
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including headache and visual field defects. In a review
of series, the most common tumor was a prolactinoma
(41%–76%), followed by growth hormone—secreting
tumor, nonfunctional tumor, and rarely adrenocortico-
tropic hormone—or thyroid-stimulating hormone—
secreting tumors [29]. Men with prolactinoma may be
unable to achieve a penile erection, whereas women may
have galactorrhea and infertility. Growth hormone-
secreting tumors (25%) result in acromegaly. Cushing’s
syndrome can also result from release of adrenocortico-
tropic hormone-like material from a pancreatic islet cell
tumor or a foregut carcinoid tumor (ectopic adrenocorti-
cotropic hormone). Prolactinomas are generally treated
by dopamine receptor agonists (bromocriptine, pergolide,
cabergoline). Transsphenoidal pituitary surgery may be
indicated to control any detectable pituitary mass lesion
in patients with MEN-1. Incompletely resected patients
may also be treated with bromocriptine.
LESS TYPICAL FEATURES
Adrenal abnormalities may occur in 27%–36% of
patients with MEN-1. The most common abnormality is a
benign, nonfunctional cortical adenoma, although adre-
nal cortical carcinomas and hyperplasia may also occur
[30]. Adrenal cortical hyperfunction may rarely be found
secondary to an adrenal tumor. Adrenal cortical neo-
plasms are usually nonfunctional in patients with MEN-1.
Thyroid adenomas also occur in approximately 5%–30%
of patients with MEN-1 and have little clinical sig-
nificance. Lipomas are seen with greater frequency in
patients with MEN-1, as are cutaneous angiofibromas and
collagenomas [31].
Gastric carcinoid tumors develop in 7%–30% of
patients with MEN-1 with ZES. They arise from gastric
enterochromaffin-like cells and thus are also call
ECLomas [32,33]. Approximately 18% have metastases,
the primary tumors are usually multiple, and they
generally pursue an indolent course. They are rare in
patients with MEN-1 without ZES.
Thymic carcinoids occur in 0%–8% of patients with
MEN-1, are almost exclusively in men, are usually
asymptomatic, and are not associated with Cushing’s or
carcinoid syndrome [34,35]. They pursue an aggressive
course with distant metastases and are an increasing
cause of death in older men with MEN-1. In contrast to
parathyroid, pituitary and pancreatic tumors, thymic
carcinoids do not show 11q13 LOH and therefore likely
have a different pathogenesis.
Bronchial carcinoid tumors occur in 0%–8% of
patients with MEN-1. Eighty percent are in women and
74% are benign; however, they are an occasional cause of
death.
FOLLOW-UP
Continued surveillance for components of MEN-1 is
necessary for all patients. This is a syndrome that one can
manage, but not cure, and thus it requires continued
attention. Patients should be assessed at least annually
and more frequently if indicated by the tempo of their
disease. Ongoing surveillance follows the same pattern
and uses the same modalities as the screening in un-
operated patients. The useful modalities include bio-
chemical hormone screening for evidence of parathyroid,
pituitary and pancreatic disease, and pancreatic imaging
with CT scan, SRS, and possibly EUS. The usual interval
between follow-up assessments for an asymptomatic
patient is 1 year.
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